CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Bharat Book Bureau: PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022

[December 05, 2013]

Bharat Book Bureau: PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022

(M2 PressWIRE Via Acquire Media NewsEdge) Summary "PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022". Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

GlobalData expects that factors such as HCV screening initiatives, increases in patient awareness, and the launch of next-generation HCV therapies will drive the growth of the HCV market in Germany.

Incivo was among the first DAA HCV regimens launched in German. The drug quickly captured market share due to its improved efficacy over the previous standard of care, a combination of peginterferon and ribavirin, for the most prevalent HCV genotype in Germany, HCV GT1. GlobalData believes that Incivo's shorter duration of triple therapy (i.e., co-administration of DAA, peginterferon, and ribavirin) enabled it to capture more market share than Merck's Victrelis, the other DAA launched around the same time as Incivo.

For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/pharmapoint-hepatitis-c-virus-germany-drug-forecast-and-market-analysis-to-2022.html Contact us at : Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Toll Free No for USA/Canada : 1-866-279-8368 Email: info@bharatbook.com Website: www.bharatbook.com Follow us on twitter: https://twitter.com/researchbook Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau Our Blog : http://blog.bharatbook.com/ For Live Chat - http://bit.ly/19m3TU4 ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to info@m2.com)).

(c) 2013 M2 COMMUNICATIONS

[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter